

# Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

NCT06752694

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Fred Hutchinson Cancer Center
<b>Enrollment</b>	20 participants

## Key Eligibility Criteria

---

### Inclusion (15)

- Age  $\geq$  40 years or ages 18 - 40 years with Hematopoietic Cell Transplantation - Specific Comorbidity Index (HCT-CI) score  $\geq$  3 necessitating a low intensity transplant or determined inability to tolerate antithymocyte globulin (ATG)
  - Diagnosis of severe acquired aplastic anemia defined as a bone marrow hypoplasia ( $<$  25% or 25-50% with  $<$  30% residual hematopoietic cells) shown by a biopsy and at least two of the three following criteria: absolute neutrophil count (ANC)  $<$   $0.5 \times 10^9/L$ , platelets  $<$   $20 \times 10^9/L$ , or absolute reticulocytes  $<$   $40 \times 10^9/L$  or
  - Non-severe acquired aplastic anemia defined as a hypocellular marrow and transfusion dependent (red cells and/or platelets)
  - Does not meet World Health Organization (WHO) criteria for myelodysplastic syndrome (MDS)
  - Ability to understand and the willingness to sign a written informed consent document
- ... and 10 more (see full listing online)

### Exclusion (9)

- Contraindication to receiving ruxolitinib including: patients who have known hypersensitivity to JAK inhibitors and excipients
  - Patients with history of myocardial infarction (MI), cerebrovascular accident (CVA) or unprovoked pulmonary embolism (PE)/deep vein thrombosis (DVT) in past 6 months
  - History of prior allogeneic transplant
  - Active or recent infection without infectious disease (ID) consult and approval
  - History of untreated tuberculosis (TB)
- ... and 4 more (see full listing online)

## Locations (1 total)

---

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States